Adam Rehman, a 13-year-old from Oldham, has expressed gratitude to the nurse who cared for him during his revolutionary £1.65 million gene-editing treatment for beta-thalassaemia. This one-time therapy, Casgevy, utilizes the Nobel Prize-winning Crispr gene-editing tool to correct faulty stem cells, offering a potential cure for the debilitating blood disorder. Previously reliant on monthly blood transfusions since infancy, Adam received the treatment in November 2024 at Royal Manchester Children’s Hospital, enabling his body to produce healthy red blood cells and granting him newfound freedom from hospital visits and chronic pain.